Emerging data have confirmed that ovarian cancer is a much more heterogeneous disease than previously recognized.
The FDA’s recent approvals of novel anti-PARP agents as maintenance therapy for patients with previously treated advanced ovarian cancer highlight an issue that has received inadequate attention in the peer-reviewed oncology literature.
Mansoor Raza Mirza, MD, discusses the initial findings and next steps for the promising niraparib plus bevacizumab combination in ovarian cancer, as well as overall advances with PARP inhibitors in the field.
Adding hyperthermic intraperitoneal chemotherapy to interval cytoreductive surgery improved relapse-free survival and overall survival for women with newly diagnosed stage III epithelial ovarian cancer.
Maurie Markman, MD, discusses the need to change the paradigm of clinical trials and FDA approvals in ovarian cancer.
Women with ER-positive advanced high-grade serous ovarian cancer assigned to maintenance therapy with letrozole were more likely to be recurrence-free at 24 months.
Robert L. Coleman, MD, discusses targeting tumor vasculature and angiogenesis in ovarian cancer.
Bradley J. Monk, MD, discusses pivotal trials, as well as the potential for immunotherapy in ovarian cancer.
The FDA has granted a priority review to a supplemental new drug application for rucaparib (Rubraca) for use as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
Patients with ovarian cancer who begin postoperative adjuvant chemotherapy within 42 days of ending neoadjuvant chemotherapy have superior survival compared to those who initiate therapy after that point.